Field-Ready, Automated Cepheid TB Test Shows Promise In Developing World
This article was originally published in The Gray Sheet
Cepheid's Xpert MTB/RIF automated nucleic acid-amplification tuberculosis and rifampin-resistance test may be a "game changer" in effectively treating TB cases in the developing world, according to a study and editorial in the Sept. 1 New England Journal of Medicine
You may also be interested in...
A clinical trial of three new tuberculosis drugs, along with one that is used in standard therapy, exemplifies FDA's evolving approach to studies that combine more than one investigational drug.
Paige’s AI has obtained CE-IVD and UKCA marks, allowing the launch of a breakthrough product that can spot biomarkers from images.